Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 413897, 10 pages
http://dx.doi.org/10.1155/2015/413897
Research Article

The Oncofetal Protein IMP3: A Novel Grading Tool and Predictor of Poor Clinical Outcome in Human Gliomas

1Division of Pathology, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy
2Division of Pathology, Ospedale Sant’Anna, 22020 Como, Italy
3Division of Neurosurgery, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy
4Department of Pathophysiology and Organ Transplant, University of Milan, 20122 Milan, Italy
5Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy

Received 23 September 2014; Revised 14 November 2014; Accepted 14 November 2014

Academic Editor: Nader Pouratian

Copyright © 2015 Alessandro Del Gobbo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Feng, Z. Zhou, J. H. Peters et al., “Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions,” Archives of Pathology and Laboratory Medicine, vol. 135, no. 8, pp. 1024–1031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Findeis-Hosey and H. Xu, “Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer,” Biotechnic and Histochemistry, vol. 87, no. 1, pp. 24–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lu, P. Vohra, P. G. Chu, B. Woda, K. L. Rock, and Z. Jiang, “An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia,” The American Journal of Surgical Pathology, vol. 33, no. 4, pp. 521–525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Del Gobbo, V. Vaira, E. G. Rocco et al., “The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung,” Journal of Thoracic Oncology, vol. 9, no. 11, pp. 1656–1661, 2014. View at Publisher · View at Google Scholar
  5. D. Lu, X. Yang, N. Y. Jiang et al., “IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer,” The American Journal of Surgical Pathology, vol. 35, no. 11, pp. 1638–1645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Vercellini, F. M. Cribiù, A. del Gobbo, M. L. Carcangiu, E. Somigliana, and S. Bòsari, “The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions,” Fertility and Sterility, vol. 99, no. 7, pp. 1974–1979, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. D. N. Louis, H. Ohgaki, O. D. Wiestler, and W. K. Cavenee, Eds., WHO Classification of Tumours of the Central Nervous System, IARC, Lyon, France, 2007.
  8. J. Haapasalo, A. Mennander, P. Helen, H. Haapasalo, and J. Isola, “Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas,” Journal of Clinical Pathology, vol. 58, no. 3, pp. 263–268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Preusser, R. Hoeftberger, A. Woehrer et al., “Prognostic value of Ki67 index in anaplastic oligodendroglial tumours—a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group,” Histopathology, vol. 60, no. 6, pp. 885–894, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. H. Boots-Sprenger, A. Sijben, J. Rijntjes et al., “Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution,” Modern Pathology, vol. 26, no. 7, pp. 922–929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Ducray, A. Idbaih, X.-W. Wang, C. Cheneau, M. Labussiere, and M. Sanson, “Predictive and prognostic factors for gliomas,” Expert Review of Anticancer Therapy, vol. 11, no. 5, pp. 781–789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Hartmann, J. Meyer, J. Balss et al., “Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas,” Acta Neuropathologica, vol. 118, no. 4, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. P. Dunn, M. L. Rinne, J. Wykosky et al., “Emerging insights into the molecular and cellular basis of glioblastoma,” Genes and Development, vol. 26, no. 8, pp. 756–784, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. T. D. Bourne and D. Schiff, “Update on molecular findings, management and outcome in low-grade gliomas,” Nature Reviews Neurology, vol. 6, no. 12, pp. 695–701, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Van Den Bent, “Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective,” Acta Neuropathologica, vol. 120, no. 3, pp. 297–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Suvasini, B. Shruti, B. Thota et al., “Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2,” Journal of Biological Chemistry, vol. 286, no. 29, pp. 25882–25890, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. V. N. Barton, A. M. Donson, D. K. Birks et al., “Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma,” Journal of Neuropathology and Experimental Neurology, vol. 72, no. 5, pp. 442–449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Barberis, C. Pellegrini, M. Cannone, C. Arizzi, G. Coggi, and S. Bosari, “Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis,” American Journal of Clinical Pathology, vol. 129, no. 4, pp. 563–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Preusser, A. Wöhrer, S. Stary, R. Höftberger, B. Streubel, and J. A. Hainfellner, “Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens,” Journal of Neuropathology and Experimental Neurology, vol. 70, no. 8, pp. 715–723, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Janiszewska, M. L. Suvà, N. Riggi et al., “Imp2 controls oxidative phosphorylation and is crucial for preservin glioblastoma cancer stem cells,” Genes and Development, vol. 26, no. 17, pp. 1926–1944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Agarwal, M. C. Sharma, P. Jha et al., “Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing,” Neuro-Oncology, vol. 15, no. 6, pp. 718–726, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Gong, B. A. Woda, and Z. Jiang, “Oncofetal protein IMP3, a new cancer biomarker,” Advances in Anatomic Pathology, vol. 21, no. 3, pp. 191–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Yaniv, A. Fainsod, C. Kalcheim, and J. K. Yisraeli, “The RNA-binding protein Vg1 RBP is required for cell migration during early neural development,” Development, vol. 130, no. 23, pp. 5649–5661, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-B. Wang, D.-F. Dong, K. Gao, and M.-D. Wang, “Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells,” Oncology Letters, vol. 7, no. 3, pp. 651–657, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Mellai, A. Piazzi, V. Caldera et al., “IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 345–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. H. Torp, “Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies,” Clinical Neuropathology, vol. 21, no. 6, pp. 252–257, 2002. View at Google Scholar · View at Scopus
  28. A. L. Johannessen and S. H. Torp, “The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas,” Pathology and Oncology Research, vol. 12, no. 3, pp. 143–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Akinleye, P. Avvaru, M. Furqan, Y. Song, and D. Liu, “Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics,” Journal of Hematology and Oncology, vol. 6, no. 1, article 88, 2013. View at Publisher · View at Google Scholar · View at Scopus